"Colorectal Cancer" THE MERCK MANUAL, [Online] December 2007 (2007-12), pages 1-5, XP002502052 Retrieved from the Internet: URL:http://www.merck.com/mmpe/print/sec02/ ch021/ch021h.html> [retrieved on 2008-10-30] (B1)

WO-A-2006/113679 (B1)

BARTZ STEVEN R ET AL: "SMALL INTERFERING RNA SCREENS REVEAL ENHANCED CISPLATIN CYTOTOXICITY IN TUMOR CELLS HAVING BOTH BRCA NETWORK AND TP53 DISRUPTIONS" MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 26, no. 24, 1 December 2006 (2006-12-01), pages 9377-9386, XP009077057 ISSN: 0270-7306 (B1)

DE TONI F ET AL: "A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia" ONCOGENE, vol. 25, no. 22, May 2006 (2006-05), pages 3113-3122, XP002502049 ISSN: 0950-9232 (B1)

EP-A- 1 662 259 (B1)

HAFNER C ET AL: "Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer" MODERN PATHOLOGY 20061021 GB, vol. 19, no. 10, 21 October 2006 (2006-10-21), pages 1369-1377, XP002487739 ISSN: 0893-3952 1530-0285 (B1)

LANDEN CHARLES N JR ET AL: "Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery" CANCER RESEARCH, vol. 65, no. 15, August 2005 (2005-08), pages 6910-6918, XP002502048 ISSN: 0008-5472 (B1)

LEVIN P A ET AL: "Liposomal delivery of EphA2 siRNA in combination with gemcitabine reduces pancreatic tumor growth and invasion" PANCREAS, vol. 33, no. 4, November 2006 (2006-11), page 477, XP002502047 & 37TH ANNUAL MEETING OF THE AMERICAN-PANCREATIC-ASSOCIATION/13TH MEETING OF THE INTERNATIONAL-ASSOCIA; CHICAGO, IL, USA; NOVEMBER 01 04, 2006 ISSN: 0885-3177 (B1)

MAO WEIGUANG ET AL: "EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, USA, DE, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 781-788, XP002343724 (B1)

MASUDA JUNKO ET AL: "Fibronectin type I repeat is a nonactivating ligand for EphA1 and inhibits ATF3-dependent angiogenesis." THE JOURNAL OF BIOLOGICAL CHEMISTRY 9 MAY 2008, vol. 283, no. 19, 9 May 2008 (2008-05-09), pages 13148-13155, XP002487740 ISSN: 0021-9258 (B1)

MAYES PATRICK A ET AL: "Overcoming drug resistance of hypoxic cancer cells and tumors via stabilization of c-Myc protein through inhibition of GSK3 beta" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, vol. 49th, 1 April 2008 (2008-04-01), page 641, XP001538924 ISSN: 0197-016X (B1)

SHAKOORI ET AL: "Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 334, no. 4, 9 September 2005 (2005-09-09), pages 1365-1373, XP005001539 ISSN: 0006-291X (B1)

SURAWSKA H ET AL: "The role of ephrins and Eph receptors in cancer" CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 15, no. 6, 1 December 2004 (2004-12-01), pages 419-433, XP004652022 ISSN: 1359-6101 (B1)

TAN JING ET AL: "Pharmacologic modulation of glycogen synthase kinase-3 beta promotes p53-dependent apoptosis through a direct bax-mediated mitochondrial pathway in colorectal cancer cells" CANCER RESEARCH, vol. 65, no. 19, October 2005 (2005-10), pages 9012-9020,8993, XP002502050 ISSN: 0008-5472 (B1)

UCKUN ET AL: "Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK)" BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 15, no. 2, 12 December 2006 (2006-12-12), pages 800-814, XP005882800 ISSN: 0968-0896 (B1)

UCKUN FATIH M ET AL: "In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH MAY 2002, vol. 8, no. 5, May 2002 (2002-05), pages 1224-1233, XP002502051 ISSN: 1078-0432 (B1)

US-B1- 6 303 652 (B1)

WO-A-2005/056766 (B1)

WO-A-2006/041902 (B1)

WO-A-2006/063164 (B1)

WO-A-2006/081418 (B1)

"Modalities of Cancer Therapy" THE MERCK MANUAL, [Online] November 2005 (2005-11), pages 1-6, XP002502053 Retrieved from the Internet: URL:http://www.merck.com/mmpe/print/sec11/ ch149/ch149b.html> [retrieved on 2008-10-30] (B1)